Tofacitinib May Have Possible Protective Effect Against ILD in RA
"Most of the biologic therapies had similar rates of developing ILD, but the JAK inhibitor tofacitinib had a reduced risk," said study first author Matthew C. Baker, MD.
Medscape Medical News
source https://www.medscape.com/viewarticle/989971?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/989971?src=rss
Comments
Post a Comment